Amit Singal, MD, MS

Articles

IMbrave-150 and HIMALAYA: Clinical Trials of Immune Checkpoint Inhibitor Combinations in HCC

January 19th 2023

The panel reviews the HIMALAYA and IMbrave-150 clinical trials of checkpoint inhibitor combination therapy strategies in advanced HCC.

Combination Therapy with Immune Checkpoint Inhibitors for HCC

January 19th 2023

A deeper dive on immune checkpoint inhibitors in HCC including review of the mechanisms of action of the IO agents.

Immune Checkpoint Inhibitors in HCC

January 12th 2023

A multidisciplinary panel discusses use of immune checkpoint inhibitors in patients with advanced HCC.

The Advent of Systemic Therapy for HCC

January 12th 2023

Drs Singal and Lewandowski review use of tyrosine kinase inhibitors, sorafenib and lenvatinib, and discuss trials that combined systemic therapy with chemoembolization.

Therapy for Locally Advanced HCC

January 5th 2023

Experts in hepatocellular carcinoma discuss treatment options for locally advanced disease.

Child-Pugh Scoring System and Liver Function Assessment

January 5th 2023

Dr Singal reviews the Child-Pugh scoring system, then Dr Lewandowski discusses the importance of considering liver function as well as disease burden when selecting a treatment strategy.

Review of Curative Treatment Strategies for HCC

December 22nd 2022

The panel shares insight as to which patients might be candidates for curative therapies such as embolization techniques and liver transplant.

Overview of Hepatocellular Carcinoma Risk Factors

December 22nd 2022

Ghassan Abou-Alfa, MD leads Robert Lewandowski, MD, FSIR, and Amit Singal, MD in a discussion of the main risk factors for hepatocellular carcinoma.

Dr. Singal on the FDA Approval of Durvalumab With Tremelimumab in Unresectable HCC

December 13th 2022

Amit Singal, MD, discusses the FDA approval of durvalumab with tremelimumab (Imjudo) in unresectable hepatocellular carcinoma.

Management of Hepatocellular Carcinoma: Future Directions in Care

November 11th 2022

Expert insight to how the field of hepatocellular carcinoma management may evolve in coming years given therapeutic combinations and ongoing clinical trials.

Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line

November 11th 2022

Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.

Treatment Options for Advanced HCC in the Second-Line and Beyond

November 4th 2022

Brief but comprehensive insight to the cornerstone second-line treatment options in the setting of recurrent advanced hepatocellular carcinoma.

Novel First-Line Immunotherapy Approaches in Advanced HCC

November 4th 2022

Panelists close out their discussion on first-line treatment options for advanced HCC with a review of single-agent and combination immunotherapy approaches.

Real-World Use of Durvalumab + Tremelimumab in Advanced HCC

October 28th 2022

In the context of clinical data from the HIMALAYA and STRIDE trials, expert oncologists review real-world use of tremelimumab + durvalumab in advanced HCC.

Patient Profile 2: A 70-Year-Old Man With Advanced HCC Treated With Durvalumab + Tremelimumab

October 28th 2022

Focusing on a second patient profile of advanced hepatocellular carcinoma, panelists consider the role of first-line tremelimumab + durvalumab.

Real-World Use of First-Line Lenvatinib Therapy in Advanced HCC

October 21st 2022

Comprehensive discussion on the real-world applications of first-line lenvatinib therapy in advanced HCC followed by its potential in combination with TACE.

Advanced HCC: Clinical Trial Data Behind First-Line Therapy Options

October 21st 2022

Expert oncologists take a look at clinical trial data as they pertain to prevalent first-line systemic therapy options in advanced hepatocellular carcinoma.

Selecting the Appropriate First-Line Therapy for Advanced HCC

October 14th 2022

In the context of the first patient profile, expert panelists consider which factors play into their selection of first-line systemic agents in advanced hepatocellular carcinoma.

Patient Profile 1: A 77-Year-Old Man with Advanced HCC Treated With Lenvatinib

October 14th 2022

Focusing on the first patient profile of advanced hepatocellular carcinoma, Andrea Casadei-Gardini, MD, reviews his selection and use of first-line lenvatinib therapy.

Advanced HCC: Updates in First-line Systemic Therapy

October 7th 2022

Moderator Josep Llovet, MD, centers discussion on advanced hepatocellular carcinoma and provides a broad overview of treatment options in the frontline setting.